EICHORPublic-registry site landscape for NCT07705737, “Rademikibart IV for Acute Asthma and COPD Exacerbation”, a Asthma Acute study sponsored by Connect Biopharm LLC. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07705737 (registry record) |
| Study title | Rademikibart IV for Acute Asthma and COPD Exacerbation |
| Official title | A Phase 2, Open-Label, Single-Arm Trial to Evaluate IV Rademikibart as an Add-on Treatment for Acute Exacerbation in Participants With Asthma and or COPD With Type 2 Inflammation |
| Sponsor | Connect Biopharm LLC |
| Condition(s) | Asthma Acute; COPD Exacerbation Acute |
| Phase | PHASE2 |
| Listed sites | 1 |
| Intervention(s) | Rademikibart |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT07705737.
Eichor generates a preliminary site-risk snapshot for NCT07705737 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
